Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "Psychedelic Drugs Market 2025-2029" has been added to ResearchAndMarkets.com's offering.
The psychedelic drugs market is poised for substantial growth, with a projected increase of USD 1.94 billion between 2024 and 2029, supported by a remarkable CAGR of 14.3%. This anticipated surge is attributed to an increasing prevalence of mental health disorders, the gradual acceptance and legalization of psychedelic substances, and enhanced government programs aimed at mental health improvements.
Companies are increasingly focused on developing next-generation therapies for psychiatric disorders, which will significantly drive market growth. Additionally, the emphasis on mergers and acquisitions and expanding therapeutic applications for psychedelics will contribute to substantial market demand in the coming years.
This comprehensive report offers a detailed analysis of the current market scenario, encompassing market size, forecasts, emerging trends, growth drivers, and challenges. It is informed by both primary and secondary information, including insights from key industry participants. The research sheds light on historical data while forecasting future market trajectories.
The psychedelic drugs market is categorized as follows:
By Type
- Ketamine
- GHB
- MDMA
- Psilocybin
- Others
By Distribution Channel
- Hospital pharmacy
- Retail pharmacy
- Others
By Application
- Treatment resistant depression
- Opiate addiction
By Route of Administration
- Oral
- Inhalation
- Injectable
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (RoW)
The report encompasses various aspects of the market, including:
- Psychedelic Drugs Market sizing
- Psychedelic Drugs Market forecast
- Psychedelic Drugs Market industry analysis
In-depth vendor analysis is a key feature of this report, aiding clients in enhancing their market position. The document provides a comprehensive examination of several leading market vendors.
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Avadel Pharmaceuticals plc
- Braxia Scientific Corp.
- COMPASS Pathways PLC
- Cybin Inc.
- HAVN Life Sciences Inc
- Jazz Pharmaceuticals PLC
- Johnson and Johnson Services Inc.
- Lykos Therapeutics
- Pfizer Inc.
- Seelos Therapeutics Inc.
- Silo Pharma Inc.
- Stella Center
The report's profound insights into upcoming trends and challenges equip companies to strategize effectively, leveraging all potential growth opportunities. Through methodical study, synthesis, and summation of various data sources, the market analysis in this report offers a well-rounded perspective informed by robust primary and secondary research. The document concludes with a detailed competitive landscape and an in-depth vendor selection methodology, utilizing both qualitative and quantitative research for precise market growth forecasting.
For more information about this report visit https://www.researchandmarkets.com/r/zi62id
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
